. The limited oral bioavailability of this "small" protease inhibitor (PI) can be overcome when it is used with low-dose ritonavir (100-200 mg twice a day).
Researchers reported on several new drugs--such as ABT-378
from Abbott Laboratories and T-20 from Trimeris Inc.--that are showing strong potential.
For example, Abbott Laboratories has a new-generation protease inhibitor known as ABT-378
that in lab tests has shown itself to be more powerful than the protease inhibitors on the market.